Schizophrenia Treatment, Brexpiprazole, Seen to Ease Agitation in Alzheimer’s Patients in Phase 3 Trial
The schizophrenia medication Rexulti (brexpiprazole) reduced agitation in patients with Alzheimer’s disease, newly released data from two Phase 3 clinical trials of the drug show. The studies highlight that efforts are ongoing to target symptoms — other than dementia itself — to improve the quality of life of Alzheimer’s…